Bohr, D.F.: Individualities among vascular smooth muscles, in Electrolytes and Cardiovascular Diseases. Edited by E. Bajnoz, Basel, Karger, 1965, pp. 342-355.
2.
Somlyo, A.P. , Somlyo, A.V.: Vascular smooth muscle. I. Normal structure, pathology, biochemistry and biophysics. Pharmacol. Rev., 20: 197, 1968.
3.
Bevan, J.A., Su, C.: Sympathetic mechanisms in blood vessels: nerve and muscle relationships. Annu. Rev. Pharmacol., 13: 269, 1973.
4.
Vanhoutte, P.M.: Heterogeneity in vascular smooth muscle, in Microcirculation . Edited by G. Kaley and B.M. Altura, Baltimore, University Park Press, 1978, vol. II, pp. 181-309.
5.
Rahwan, R.G. , Piascik, M.F., Witiak, D.T.: The role of calcium-antagonism in the therapeutic action of drugs. Can. J. Physiol. Pharmacol., 57: 443, 1979.
6.
Godfraind, T. , Kaba, A.: Blockade or reversal of the contraction induced by calcium and adrenaline in depolarized arterial smooth muscle. Br. J. Pharmacol., 36: 549, 1969.
7.
Van Nueten, J.M.: Comparative bioassay of vasoactive drugs using isolated perfused rabbit arteries. Eur. J. Pharmacol. , 6: 286, 1969.
8.
Church, J., Zsotér, T.T.: Calcium-antagonistic drugs. Mechanism of action. Can. J. Physiol. Pharmacol., 58: 254, 1980.
9.
Kaiman, M., Shibata, S.: Calcium-influx and spontaneous phasic contractions of portal veins after treatment with reserpine, 6-OH-dopamine and cocaine. Can. J. Physiol. Pharmacol., 56: 199, 1978.
10.
Van Nueten, J.M., Van Beek, J., Janssen, P.A.J.: Effect of flunarizine on calcium-induced responses of peripheral vascular smooth muscle. Arch. Int. Pharmacodyn. Ther., 232: 42, 1978.
11.
Vanhoutte, P.M., Verbeuren, T.J., Van Nueten, J.M.: Effect of lidoflazine on systemic arteries and veins. Angiology (in press).
12.
Van Breemen, C.: Calcium requirement for activation of intact aortic smooth muscle. J. Physiol., 272: 317, 1977 .
13.
Shepherd, J.T. , Vanhoutte, P.M.: Veins and their Control. Philadelphia, W.B.Saunders, 1975 , pp. 1-269.
14.
Van Nueten, J.M. , Wellens, D.: Mechanisms of vasodilatation and antivasoconstriction . Angiology, 30: 440, 1979.
15.
Van Nueten, J.M. , Van Beek, J., Vanhoutte, P.M.: Inhibitory effect of lidoflazine on contractions of isolated canine coronary arteries caused by norepinephrine, 5-hydroxytryptamine, high potassium, anoxia and ergonovine maleate. J. Pharmacol. Exp. Ther., 213: 179, 1980.
16.
Vanhoutte, P.M. , Van Nueten, J.M.: The pharmacology of lidoflazine. In Myocardial protection and exercise tolerance: the role of lidoflazine, a new anti-anginal agent. Edited by G. Towse , London. The Royal Society of Medicine and Academic Press Inc. Ltd. International Congress and Symposium Series No 29, 1980 pp. 61-77.
17.
Gaddum, J.H. , Picarelli, Z.P.: Two kinds of tryptamine receptors. Br. J. Pharmacol., 12: 323, 1957.
18.
Gyermek, L. : 5-Hydroxytryptamine-antagonists. Pharmacol. Rev., 13: 399, 1961.
19.
Page, I.H.: Serotonin (5-hydroxytryptamine) ; the last four years. Physiol. Rev., 38: 277, 1958.
20.
Somlyo, A.P. , Somlyo, A.V.: Vascular smooth muscle. II. Pharmacology of normal and hypertensive vessels. Pharmacol. Rev., 22: 251, 1970.
21.
Bohr, D.F., Goulet, P.L., Taquini, A.C.: Direct tension recording from smooth muscle of resistance vessels from various organs. Angiology, 12: 478, 1961.
22.
Toda, N., Fujita, Y.: Responsiveness of isolated cerebral and peripheral arteries to serotonin, norepinephrine, and transmural electrical stimulation. Circ. Res., 33: 98, 1973.
23.
Müller-Schweinitzer, E.: Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine. Naunyn-SchmiedebergsArch. Pharmacol., 292: 113, 1976.
24.
Van Nueten, J.M., Xhonneux, R., Janssen, P.A.J.: Preliminary data on antiserotonin effects of oxatomide, a novel anti-allergic compound. Arch. Int. Pharmacodyn. Ther., 232: 217, 1978.
25.
Leysen, J.E. , Awouters, F., Kennis, L., Laduron, P.M., Vandenbeek, J. and Janssen, P.A.J.: Receptor binding profile of R 41468, a novel antagonist at 5-HT2 receptors. Life Sci.1981 (in press).
26.
Apperley, E. , Feniuk, W., Humphrey, P.P.A., et al.: Evidence for two types of excitatory receptor for 5-hydroxytryptamine in dog isolated vasculature. Br. J. Pharmacol., 68: 215, 1980.
27.
Fozard, J.R. : Comparative effects of four migraine prophylactic drugs on an isolated extracranial artery. Eur. J. Pharmacol. , 36: 127, 1976.
28.
Van Reempts, J., Borgers, M., Xhonneux, R., et al.: The inhibition of ischemic lesions of the rat gastric mucosa by a novel serotonin-antagonist. A light and electron microscopic study. Angiology (in press).
29.
De La Lande, I.S., Cannell, V.A., Waterson, J.G.: The interaction of serotonin and noradrenaline on the perfused artery. Br. J. Pharmacol., 28: 255, 1966.